Chinese vaccine considered safe and with immune response in the first trials

2020-10-16

The first tests on BBIBP-CorV involved more than 600 volunteers.

A vaccine candidate against Covid-19 that is being developed in China has shown to be safe and able to induce an immune response in healthy volunteers in the early stages of the clinical trial, according to the results released today.

The conclusions of the initial phase clinical trial, which were published today in the scientific journal “The Lancet Infectious Diseases”, also point to positive levels of tolerance to all doses tested, with no reports of serious adverse reactions among the participants.